Haemonetics (HAE) AI Stock Analysis

• Market Cap: $3.92B
• Dividend Yield: N/A
• Average Volume (3M): 1.00M
• Price to Earnings (P/E): 25.4
• Beta (1Y): 0.56
• Revenue Growth: -2.45%
• EPS Growth: 41.50%
• Country: US
• Employees: 3,657
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.27
• Shares Outstanding: 46,809,673
• 10 Day Avg. Volume: 616,992
• 30 Day Avg. Volume: 1,002,724
• PEG Ratio: 0.44
• Price to Book (P/B): 3.87
• Price to Sales (P/S): 2.34
• P/FCF Ratio: 22.33
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 2.43
• Enterprise Value/Gross Profit: 4.14
• Enterprise Value/Ebitda: 8.60
• 1Y Price Target: $84.43
• Price Target Upside: -3.13% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 4.91
• Revenue Forecast (FY): $1.32B

• Rating: 70 Outperform
• Price Target: $74.00 ▼(-15.10% Downside)

Haemonetics' overall stock score is driven by strong earnings call performance and robust financial metrics, particularly in profitability and cash flow. However, technical indicators suggest caution due to overbought conditions, and valuation metrics indicate moderate attractiveness. The company's high leverage and revenue decline are areas to watch.

Positive Factors

Organic Revenue Growth

Strong organic growth indicates robust demand for core products, enhancing long-term revenue potential and market position.

Margin Expansion

Improved margins reflect operational efficiency and pricing power, supporting sustainable profitability and competitive advantage.

Plasma Segment Performance

Strong growth in the plasma segment underscores the effectiveness of technology upgrades, boosting long-term revenue streams.

Negative Factors

Revenue Decline

Revenue decline due to portfolio transitions may signal challenges in adapting to market changes, impacting short-term financial performance.

High Leverage

High leverage can strain financial flexibility and increase risk, potentially affecting long-term stability and investment capacity.

Interventional Technologies Challenges

Decline in interventional technologies highlights competitive and operational challenges, potentially limiting growth in this segment.

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation (HAE) is a global healthcare company focused on providing innovative solutions for blood and plasma management. The company primarily operates in the healthcare sector, delivering a range of products and services that enhance the safety, efficiency, and effectiveness of blood collection, processing, and transfusion. Haemonetics' core offerings include blood collection and processing systems, software solutions for blood management, and products related to the donation and transfusion of blood and blood components.

How the Company Makes Money

Haemonetics generates revenue through several key streams including the sale of medical devices and consumables for blood collection and processing, software solutions for blood management, and services related to these products. The company earns significant income from its hematology products, particularly those used in blood and plasma centers. Additionally, Haemonetics has established partnerships with various healthcare organizations, enhancing its market reach and operational capabilities. Revenue is further supported by ongoing service agreements, maintenance contracts, and training services for healthcare providers, which create a recurring revenue model.

Haemonetics Financial Statement Overview

Summary

Haemonetics demonstrates strong profitability and cash flow management with a consistent gross profit margin and robust cash conversion efficiency. However, the company faces challenges with declining revenue growth and high leverage.

Income Statement

Haemonetics shows strong profitability with a consistent gross profit margin around 56% in TTM, and a stable net profit margin of 12.1%. However, the revenue growth rate has declined by 1.1% in TTM, indicating a potential slowdown in sales growth. EBIT and EBITDA margins remain healthy, reflecting efficient operations.

Balance Sheet

The company has a high debt-to-equity ratio of 1.39 in TTM, suggesting significant leverage, which could pose risks if not managed carefully. However, the return on equity is robust at 18.7%, indicating effective use of equity to generate profits. The equity ratio is moderate, reflecting a balanced asset structure.

Cash Flow

Haemonetics demonstrates strong cash flow management with a 32.8% growth in free cash flow in TTM. The operating cash flow to net income ratio is 0.43, and the free cash flow to net income ratio is 0.84, indicating good cash conversion efficiency. This positions the company well for future investments and debt servicing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.33B	1.36B	1.31B	1.17B	993.20M	870.46M
Gross Profit	779.57M	778.55M	711.91M	622.87M	530.77M	428.45M
EBITDA	375.13M	355.99M	295.45M	252.01M	191.72M	184.38M
Net Income	168.19M	167.68M	117.56M	115.40M	43.38M	79.47M
Balance Sheet
Total Assets	2.44B	2.45B	2.20B	1.93B	1.86B	1.82B
Cash, Cash Equivalents and Short-Term Investments	296.43M	306.76M	178.80M	284.47M	259.50M	192.31M
Total Debt	1.22B	1.22B	807.79M	765.89M	780.78M	778.28M
Total Liabilities	1.59B	1.63B	1.24B	1.12B	1.11B	1.09B
Stockholders Equity	849.17M	820.84M	959.96M	818.00M	749.42M	731.67M
Cash Flow
Free Cash Flow	256.08M	142.45M	115.45M	162.87M	75.75M	71.77M
Operating Cash Flow	289.04M	181.72M	181.75M	273.06M	172.26M	108.81M
Investing Cash Flow	-62.80M	-161.90M	-322.39M	-143.79M	-86.34M	-425.44M
Financing Cash Flow	-229.06M	108.82M	38.16M	-100.36M	-15.75M	367.45M

Haemonetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 87.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Positive. The current price of 87.16 is above the 20-day moving average (MA) of 79.32, above the 50-day MA of 63.36, and above the 200-day MA of 64.01, indicating a bullish trend. The MACD of 6.18 indicates Positive momentum. The RSI at 89.35 is Negative, neither overbought nor oversold. The STOCH value of 77.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HAE.

Haemonetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	75 Outperform	$1.95B	41.90	15.02%	0.96%	13.07%	27.98%
HAE	70 Outperform	$3.92B	25.43	19.47%	―	-2.45%	41.50%
MMSI	68 Neutral	$4.94B	43.72	8.30%	―	11.49%	-2.89%
TFX	68 Neutral	$4.83B	―	-7.90%	1.04%	5.43%	-245.18%
ICUI	61 Neutral	$3.52B	-458.38	-0.35%	―	-0.81%	93.27%
QDEL	54 Neutral	$1.86B	―	-44.21%	―	-3.43%	38.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Haemonetics Corporate Events

Haemonetics Reports Improved Profitability Amid Revenue Decline

Haemonetics Corporation is a global medical technology company specializing in innovative healthcare solutions, including hospital technologies, plasma collection systems, and blood component collection products.

Haemonetics’ Earnings Call: Growth Amid Challenges

Haemonetics’ recent earnings call painted a mixed picture, showcasing robust growth in certain segments while highlighting challenges in others. The company demonstrated strong performance in its Plasma and TEG segments, contributing to significant margin expansion and financial flexibility. However, difficulties in the Interventional Technologies segment and a decline in Blood Center revenue posed notable concerns. Overall, the positive aspects slightly outweighed the negatives, but the challenges remain a significant consideration.

Haemonetics Reports Q1 Fiscal 2026 Earnings

Haemonetics Corporation is a global medical technology company specializing in innovative healthcare solutions, including plasma collection technologies and hospital technologies aimed at enhancing patient outcomes. In its first quarter of fiscal 2026, Haemonetics reported a 4.4% decrease in revenue to $321.4 million, with a slight organic revenue increase of 0.5%. The company achieved a gross margin of 59.8%, up from 52.0% in the previous year, driven by pricing benefits and product mix improvements.